The development of targeted therapies for melanoma has seen several promising compounds, most notably Vemurafenib, RO5185426 (Cobimetinib), RG7204 (Selumetinib), and PLX4032 (Plexxicon-4032). While all four focus the BRAF V600 mutation, a key driver in many melanomas, they exhibit subtle yet sign

Ibritumomab, also Zevalin, represents the novel form of targeted radiotherapy used to combat certain kinds of non-Hodgkin's lymphoma , particularly recurring follicular lymphoma cases . It is an monoclonal antibody conjugated to radioactive yttrium, the radioactive element that releases precise r